Hims & Hers ZAVA Acquisition Deal Expands Its Market Opportunity By $52 Billion: Analyst

Hims & Hers Health (HIMS) has agreed to acquire ZAVA, a European digital health platform, in an all-cash deal expected to close in the second half of 2025, expanding Hims & Hers' footprint into the UK, Germany, France, and Ireland. Needham analysts estimate ZAVA's annual revenue at approximately $100 million and project a $52.1 billion weight loss market opportunity in ZAVA's existing regions, reiterating a Buy rating on HIMS with a price target increase to $65; however, HIMS stock is currently down 2.24% at $53.51.

Analysis

Hims & Hers Health, Inc. (HIMS) has announced an all-cash acquisition of ZAVA, a European digital health platform, a strategic move poised to significantly expand its international footprint into the United Kingdom, Germany, France, and Ireland. The deal, funded from Hims & Hers' balance sheet, is expected to close in the second half of 2025 and become accretive by 2026. ZAVA demonstrated substantial scale in 2024, serving over 1.3 million customers and delivering nearly 2.3 million consultations. While HIMS did not disclose ZAVA's financial metrics, Needham analysts estimate ZAVA's annual revenues to be approximately $100 million. Furthermore, Needham highlights a considerable market opportunity, projecting the weight loss segment alone in ZAVA’s current markets could expand Hims & Hers' Total Addressable Market by $52.1 billion. In response to this development, Needham reiterated a Buy rating for HIMS and raised its price target to $65 from $61, underscoring the potential for European markets to serve as a durable long-term growth vector. Despite this positive outlook and strong analyst sentiment, HIMS stock experienced a slight downturn, trading 2.24% lower at $53.51 at the last check.

Key Decisions for Investors

• Investors should view the ZAVA acquisition as a key strategic initiative for Hims & Hers that significantly expands its international reach and total addressable market, with accretion expected by 2026.
• Consider the current stock price pullback in HIMS, despite positive analyst commentary and a raised price target, as a potential opportunity for long-term investors, whilst acknowledging the deal's closing timeline extends to the second half of 2025.
• Monitor Hims & Hers' execution in integrating ZAVA and rolling out its branded personalized digital health services across the new European markets, particularly in dermatology, weight loss, sexual health, and mental health.